Retatrutide cannot legally be sold anywhere in the world, but you would never know that based on the ease in which consumers can purchase products claiming to be the real thing.
Before the medication has even completed the regulatory process, purported versions are already being advertised online and in storefronts, shipped across borders, and put directly into consumers’ hands. The consequences are already evident, with reported hospitalizations linked to purported retatrutide in multiple countries.
Around the world, regulators are responding with raids, seizures, sales bans, financial penalties, and other enforcement actions aimed at disrupting the manufacture, distribution, and sale of unauthorized retatrutide.
But in the United States, federal regulators are falling behind their international counterparts. While the Food and Drug Administration (FDA) has recently issued a few warning letters to sellers of illegal retatrutide, more must be done to aggressively disrupt the influx of counterfeit and illicit products before more patients are put in harm’s way.
Other Countries Aren’t Waiting to Act
Australia
- June 19, 2026: Made unapproved peptides, including retatrutide, a priority area for compliance and enforcement.
- June 26, 2026: Issued a health alert following serious toxicity associated with purported retatrutide.
- August 2026: Executed search warrants and seized more than $120,000 in illicit products, including retatrutide, from an alleged social-media seller who had previously been warned.
Brazil
- January 2026: Prohibited the import and sale of purported retatrutide products.
- April 2026: Executed 45 search-and-seizure warrants across 12 states, seizing retatrutide and identifying evidence of its distribution.
- September 1, 2026: Ordered the seizure of all products from an online seller marketing purported retatrutide and prohibited their manufacture, importation, distribution, sale and advertising.
- September 2, 2026: Executed a search-and-seizure warrant in an investigation into clandestine importation and online sales of unauthorized medicines, including retatrutide.
Canada
- 2026: Seized unauthorized retatrutide from online sellers and worked with border authorities to intercept unauthorized peptide shipments.
- June 2026: Secured a permanent injunction against a repeat seller of unauthorized injectable peptides after earlier enforcement failed to stop the conduct.
China
- May 2026: Dismantled 10 illegal manufacturing and sales operations, arrested 55 suspects and seized more than 40,000 purported weight-loss injections, including retatrutide.?
France
- July 2026: Prohibited the importation and distribution of purported retatrutide products.
Hong Kong
- February 2026: Customs uncovered nine controlled-medicine smuggling cases, arrested four people and seized approximately 100,000 vials, 340,000 tablets and 60 kg of medicines worth more than HK$140 million; seized products reportedly included purported retatrutide.
Malaysia
- June 2026: Issued a warning letter over social-media advertising of purported retatrutide and removed 51 related online listings.
- January–July 2026: Conducted 30 raids involving weight-loss products, including 17 targeting online sales.
- 2026: Removed 209 weight-loss product advertisements, including listings claiming to contain retatrutide, from e-commerce platforms.
Netherlands
- August 24, 2026: Ordered an online seller to immediately stop selling and distributing retatrutide following reports of adverse effects.
- August 31, 2026: Imposed penalties of €10,000 per day, up to €200,000, after the seller continued offering retatrutide.
Paraguay
- December 2025: Seized purported retatrutide.
Saudi Arabia
- March 2026: Detained gym trainers accused of promoting and selling unregistered peptides and located a warehouse containing unauthorized products, including retatrutide.
UAE
- July 2026: Took regulatory action against 71 sources accused of marketing, promoting or selling unauthorized peptide products, including retatrutide.?
United Kingdom
- August 2025: Seized roughly £32,000 in suspected counterfeit weight-loss drugs, including purported retatrutide.
- October 2025: Raided an illicit manufacturing facility and seized more than 2,000 unlicensed retatrutide and tirzepatide pens.
- February 2026: Made arrests in an investigation into illegal weight-loss medicines.
- May 2026: Arrested two suspects and seized approximately 12,000 doses of unlicensed weight-loss medicines, including retatrutide.
The U.S. Has More Work to Do
There is no ambiguity about retatrutide’s legal status in the United States. It is not FDA-approved and cannot legally be sold or compounded. Labeling a product “research use only” – as many illegal sellers do – does not create a workaround or safe harbor when it is being sold for human use.
FDA has warned consumers about unapproved GLP-1 products and issued warning letters to companies selling purported retatrutide. Yet the product remains readily available through channels outside the regulated drug supply chain. Warnings are important, but the international response demonstrates how much further enforcement can go.
The United States should focus on disrupting the operations and supply chains that allow these products to proliferate:
- Stop illegal products before they reach patients. FDA, Customs and Border Patrol, Department of Justice, and other authorities should more aggressively intercept unauthorized retatrutide, investigate domestic manufacturing and distribution, and use seizures, injunctions and other available tools to remove illegal products from circulation.
- Make repeat violations carry real consequences. Sellers and distributors that continue operating after being put on notice should face escalating enforcement resulting in the ceasing of operations.
- Follow the entire supply chain. Enforcement should reach manufacturers, ingredient suppliers, importers, distributors, and other entities enabling unauthorized products to reach U.S. consumers—not simply the individual seller or listing where a product is found.
- Close off pathways to consumers. Regulators should address unlawful promotion and sales across websites, social media, and online marketplaces while also targeting unauthorized products moving through other channels. Agencies should work with tech platforms, payment processors, and other intermediaries to make it harder for bad actors to simply shift from one channel to another.
Retatrutide Is a Test Case for What Comes Next
Retatrutide is unlikely to be the last highly anticipated medicine to attract demand before FDA has determined that it is safe and effective. Without meaningful enforcement, the same pattern could emerge around the next investigational drug.
That risks normalizing a market in which unapproved medicines reach consumers outside the safeguards of scientific review and the regulated drug supply chain.
The United States has an opportunity to intervene before that happens. Enforcement should match the speed with which this market has developed, targeting not only individual violations but the networks that allow unauthorized products to reach patients.
Retatrutide is still investigational. The illicit market surrounding it is already here. The United States should act now to prevent that market from becoming an accepted path for unapproved medicines to reach patients.